Centrexion Therapeutics CNTX 深 沪
已收盘 12-12 16:00:00 美东时间
1.04
0.000
0.00%
华盛通- 最 高1.06
- 今 开1.04
- 成交量 54.66万股
- 最 低 1.02
- 昨 收 1.04
- 总市值 9329.24万
- 52周最高 1.55
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 0.49
- 委 比 93.67%
- 总股本 8970.42万
- 历史最高 10.87
- 量 比 1.00
- 振 幅 3.85%
- 历史最低 0.47
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
11-06 19:52
Context Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 9.89 percent. This is a 54.55 percent increase over losses of $(0.22) per share
11-06 06:02
Context Therapeutics Regains Nasdaq Compliance
The latest update is out from Context Therapeutics ( ($CNTX) ). Context Therape...
10-21 06:25
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.
10-16 20:40
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Candel Therapeutics announced encouraging interim data from its ongoing phase 1b clinical trial of CAN-3110 for recurrent glioblastoma, with updated survival data showing a median overall survival of 11.8 and 12.0 months for arms A and B, respectively. CAN-3110, a viral immunotherapy, was shown to dynamically remodel the tumor microenvironment, with biopsy analyses revealing immune activation and tumor cell replacement by immune cells. A complete...
10-14 12:05
Context Therapeutics To Present Cancer Immunotherapy Data At SITC 2025
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced two posters will
10-06 19:38
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Context Therapeutics will present two posters at the Society for Immunotherapy of Cancer’s 40th Annual Meeting on November 7–9, 2025, in National Harbor, MD. The posters will highlight CT-95, a Phase 1 clinical trial targeting mesothelin in solid tumors, and preclinical data for CT-202, a pH-dependent TCE targeting Nectin-4. Both presentations will discuss the potential of these T cell engaging bispecific antibodies for treating various cancers.
10-06 11:30
